Anton Porsteinsson Selected Research

ALZ-801

12/2020

Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anton Porsteinsson Research Topics

Disease

8	Alzheimer Disease (Alzheimer's Disease) 12/2020 - 12/2002
4	Dementia (Dementias) 08/2021 - 11/2005
3	Disease Progression 12/2020 - 12/2002
2	Cognitive Dysfunction 08/2021 - 01/2017
1	Edema (Dropsy) 12/2020
1	Amyloid Plaque 12/2020
1	Diarrhea 08/2011
1	Body Weight (Weight, Body) 08/2011
1	Sleepiness 08/2011
1	Psychotic Disorders (Schizoaffective Disorder) 08/2011
1	Tremor (Tremors) 08/2011

Drug/Important Bio-Agent (IBA)

4	Valproic Acid (Depakote)FDA LinkGeneric 08/2011 - 12/2002
2	Amyloid (Amyloid Fibrils)IBA 12/2020 - 01/2017
2	Biomarkers (Surrogate Marker)IBA 12/2020 - 05/2014
2	Apolipoproteins E (ApoE)IBA 12/2012 - 11/2012
1	lecanemabIBA 12/2020
1	ALZ-801IBA 12/2020
1	gantenerumabIBA 12/2020
1	aducanumabIBA 12/2020
1	Amyloid beta-PeptidesIBA 12/2020
1	Apolipoprotein E4IBA 12/2020
1	Methylphenidate (Ritalin)FDA LinkGeneric 01/2018
1	ApolipoproteinsIBA 12/2012

Therapy/Procedure

1	Cognitive Training 08/2021
1	Home Nursing (Nursing, Home) 11/2005
1	Therapeutics 12/2002